Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) currently has a daily average trading volume of 1.91M but it saw 4012811 shares traded in last market. With a market cap of 16.77M USD, the company’s current market price of $0.20 came rising about 4.14 while comparing to the previous closing price of $0.19. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.80 and as low as $0.17.
Taking a look at 20-day trading activity of Tonix Pharmaceuticals Holding Corp (TNXP) gives us an average price of $0.3138, while its current price level is -94.78% below from 52-week high level whereas it is 18.86% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.3310 while that of 200 days or SMA-200 reads an average of $0.7042. A closer look into the stock’s movement over the week reveals that its volatility is standing at 30.53% during that period while stretching the period over a month that decreases to 13.27%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 25.93 which implies that the stock is in oversold territory.
ROTH Capital upgraded its recommendation for the stock as a “Buy” from “Neutral” on April 18, 2019 while assigning a price target of $4. ROTH Capital issued its recommendations for the stock as it upgraded the price target for the stock is $6.
Over the week, TNXP’s stock price is moving -40.75% down while it is -47.64% when we observe its performance for the past one month. Year-to-date it is -50.74% down and over the past year, the stock is showing a downside performance of -94.63%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of -$0.86 beat the consensus estimate of -$1.64 for the same. For TNXP, analysts are forecasting an EPS-growth rate of 54.20% for current year and estimate for EPS growth in next year is 61.50%. In next quarter, company is expected to be making quarterly sales of $7.9 million as analysts are expecting the sales for current fiscal year at $16.77 million and seeing the company making $24.5 million in sales next year. Moreover, analysts are in estimates of $7.5 million for current-quarter revenue.
Currently, Tonix Pharmaceuticals Holding Corp’s total number of outstanding shares is 84.49M with 0.01% of that held by the insiders while 28.61% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -103.50% and return on equity (ROE) at -74.61%. Stock’s beta reads 2.21. Stock has a price to book (P/B) ratio of 0.11 while price to sale or P/S ratio amounts to 2.16. Its return on asset (ROA) is -61.38% on average.
